Effect of intravitreal ranibizumab, aflibercept and dexamethasone on corneal astigmatism

Poster Details

First Author: S.Kerci TURKEY

Co Author(s):    O. Karti   M. Zengin                          

Abstract Details


To evaluate surgically induced astigmatism after an intravitreal ranibizumab (IVR), aflibercept (IVA) and dexamethasone (IVD) injection.


prospective study


Sixty eyes of 60 patients who underwent IVR (34 patients) , IVA (16 patients) and IVD (10 patients) injection due to age-related macular degeneration (wet form) or macular edema were included in this study. Patients' pre- and postoperative detailed ophthalmologic examinations were done and topographic keratometric values (K1, K2) were noted. Pre- and postoperative measurements were compared.


The mean preoperative astigmatism of IVR, IVA and IVD groups were found to be K1; 43.20 ± 1.45 D, K2; 44.25 ± 1.61 D, K1; 42.96 ± 1.46 D, K2; 43.90 ± 1.29 D and K1; 43.00 ± 1.21 D, K2; 43.77 ± 1.12 D, respectively. The mean postoperative asitgmatism of these groups were K1:43.03 ± 1.55 D, K2:44.28 ± 1.70 D in IVR group, K1:43.01 ± 1.50 D, K2:43.96 ± 1.35 D in IVA group and K1: 42.91 ± 1.29 D, K2: 43.83 ± 1.22 D in IVD group, respectively. The difference between preoperative and postoperative K values in three groups was not statistically significant (ranibizumab p1=0.322, p2=0.344; aflibercept p1=0.464, p2=0.447; dexamethasone p1=0.444, p2=0.460).


Intravitreal injection is a minimally invasive ophthalmologic procedure. Therefore; it doesn’t cause statistically significant induced astigmatism.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy